1YTop 25% of the group
Rank 1 of 63 funds
Return +62.13%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 1No. 1 is SCBGENOME(E) +62.13%
SCB Genomic Revolution
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
SCBGENOME(SSFE) is a fund of funds that puts 91.08% into units of other funds, spread across several funds
This fundSCBGENOME(SSFE)This fund's manager selects the funds and adjusts their weights. The funds it holds also charge their own fees
All funds, as disclosed in the AMC fact sheet · The stocks these funds hold are shown below · This fund's performance therefore depends on the funds it holds
Twist Bioscience TWST10.03%
10x Genomics TXG8.02%Over the past year it was in the top 25% of its group; over 3 years it returned +21.97% per year (Top 25% of the group)
No. 1 is SCBGENOME(E) +62.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | MAX |
|---|---|---|---|---|---|---|---|---|
| +69.56% | −3.06% | +1.33% | −6.29% | +25.66% | +60.45% | +62.13% | +81.46% | +44.62% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar |
|---|
Largest drawdown in the selected period −59.36% Previous peak 15 Aug 2022 (NAV 5.4311) → Trough 8 Apr 2025 (NAV 2.2072) · Back to the previous peak on 17 Sep 2026, after 1 year 5 months
Currently −10.78% from the peak NAV of 6.1050 (5 Oct 2026)
Over 3 years, SCBGENOME(SSFE) returned 0.55 per unit of volatility, ranking 16 of 37 funds · The highest is TBIOTECH (0.88)
กองทุนมีนโยบายเน้นลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศ เช่น หน่วย CIS และ/หรือหน่วยของกองทุนอีทีเอฟ (ETF) เป็นต้น ที่มีนโยบายเน้นลงทุนในหลักทรัพย์และ/หรือตราสารของบริษัทที่มีความเกี่ยวข้องกับวิทยาการทางด้านพันธุวิศวกรรม (Genomic Revolution theme) ซึ่งมุ่งเน้นและคาดว่าจะได้รับประโยชน์จากการพัฒนาค… Its largest holdings are หน่วยลงทุน ARK GENOMIC REVOLUTION ETF 80.05% · หน่วยลงทุน ISHARES GENOMICS IMMUNOLOGY AND HEALTHCARE ETF 23.05% (fact sheet 31 Aug 2026)
Risk level 7 of 8 (High risk). Since 10 Jun 2022, its NAV has fallen as much as −59.36% from its peak.
Actual total expense ratio (TER) 0.12% a year, against a ceiling of 1.83%. Management fee 0.00%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 31 Jul 2026)
It has a dividend policy but has not paid any dividends yet
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Tempus AI Inc Class A common… TEM7.15%
CRISPR Therapeutics CRSP4.20%
Absci ABSI4.05%
Guardant Health GH3.69%
Natera NTRA3.63%
Illumina ILMN3.60%
CareDx CDNA3.48%Twist Bioscience TWSTMakes synthetic DNA on silicon chips for drug and genetics research
10x Genomics TXGMakes single-cell analysis instruments and reagents for biology research
CRISPR Therapeutics CRSPHospitals, medicines and medical equipment
Absci ABSIHospitals, medicines and medical equipment
Natera NTRAIllumina ILMNCareDx CDNABased on each ETF's actual share of the fund's value · Weighted by each fund held × the stocks that fund holds, covering 113% of the money invested in other funds. Uses each fund's top 10, so figures are a minimum · ARK Genomic Revolution as of 22 Oct 2026 · iShares Genomics Immunology and Healthcare as of 22 Oct 2026 · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +21.97% per year
| Apr |
|---|
| May |
|---|
| Jun |
|---|
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | +5.2 | +0.2 | −8.5 | +9.5 | +12.2 | +20.5 | −7.6 | +21.3 | +13.7 | −4.0 | −3.0 | · | +69.6* |
| 2025 | +9.6 | −5.8 | −14.0 | +3.8 | −5.2 | +11.7 | −0.5 | +3.3 | +10.2 | +10.5 | +1.8 | −7.4 | +15.3 |
| 2024 | −13.5 | +10.3 | −6.2 | −15.4 | +4.2 | −3.9 | +11.2 | −3.4 | −4.2 | −6.0 | +10.3 | −9.2 | −26.5 |
| 2023 | +16.1 | −9.7 | −3.0 | −2.7 | +7.1 | +5.4 | +7.4 | −12.7 | −12.6 | −17.5 | +18.1 | +19.5 | +6.6 |
| 2022 | · | · | · | · | · | +6.7 | +21.4 | −6.3 | −6.9 | +2.9 | −6.3 | −13.3 | −5.5* |
Minimum first purchase 1 THB, subsequent purchases 1 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+4
Hedged at the manager's discretion. As of 31 Jul 2026, 57.68% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · SCBGENOME(SSFE): pays dividends, TER 0.12% · SCBGENOME(A): no dividends, TER 0.62% · SCBGENOME(D): see the conditions in the prospectus · SCBGENOME(E): no dividends, TER 0.12% · SCBGENOME(IN): see the conditions in the prospectus · SCBGENOME(P): see the conditions in the prospectus · SCBGENOME(R): see the conditions in the prospectus · SCBGENOME(SSF): pays dividends, TER 0.62%